HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cleland, J. G. F. Articles by Clark, A. L. Search for Related Content PubMed PubMed Citation Articles by Cleland, J. G. F. Articles by Clark, A. L.

Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure

Too many cooks will spoil the broth^*

^* University of Hull, Kingston-Upon-Hull, United Kingdom

View larger version (45K): [in a new window]   Figure 1 Effects of therapy on two-year mortality in landmark trials of heart failure of varying symptomatic severity. ßB = beta-blocker; AA = aldosterone antagonist; ACEi = angiotensin-converting enzyme inhibitor; NYHA = New York Heart Association; Prev. = Prevention; Treat. = Treatment. CIBIS-II = Cardiac Insufficiency Bisoprolol Study-part II; CONSENSUS = Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS = Carvedilol Prospective Randomised Cumulative Survival trial; EPHESUS = Eplerenone's Neurohormonal Efficacy and Survival Study; MERIT = Metoprolol CR/XL Randomized Intervention Trial in Heart Failure; RALES = Randomized Aldactone Evaluation Study; SOLVD = Studies Of Left Ventricular Dysfunction.

View larger version (34K): [in a new window]   Figure 2 The cumulative effects of triple therapy with angiotensin-converting enzyme inhibitors, beta-blockers, and aldosterone antagonists over two years showing the potential number of lives saved over two years. These studies also showed a reduction in hospitalization and an improvement in patients' symptoms amongst survivors.